Enhanced cell survival and therapeutic benefits of IL-10-expressing multipotent mesenchymal stromal cells for muscular dystrophy

Yuko Nitahara Kasahara  
Nippon Medical School: Nihon Ika Daigaku

Mutsuki Kuraoka  
Nippon Veterinary and Life Science University: Nihon Jui Seimei Kagaku Daigaku

Yuki Oda  
Nippon Medical School: Nihon Ika Daigaku

Hiromi Hayashita Kinoh  
Nippon Medical School: Nihon Ika Daigaku

Shin'ichi Takeda  
National Institute of Neuroscience, National Center of Neurology and Psychiatry

Takashi Okada (✉ t-okada@ims.u-tokyo.ac.jp)  
Nippon Medical School: Nihon Ika Daigaku  https://orcid.org/0000-0002-2910-3797

Research

**Keywords:** Mesenchymal stromal cells, IL-10, DMD

**DOI:** https://doi.org/10.21203/rs.3.rs-73149/v3

**License:** ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Multipotent mesenchymal stromal cells (MSCs) are potentially therapeutic for muscle disease because they can accumulate at the sites of injury and act as immunosuppressants. MSCs are attractive candidates for cell-based strategies that target diseases with chronic inflammation, such as Duchenne muscular disease (DMD). We focused on the anti-inflammatory properties of IL-10 and hypothesized that IL-10 could increase the typically low survival of MSCs by exerting a paracrine effect after transplantation.

Methods: We developed a continuous IL-10 expression system of MSCs using an adeno-associated virus (AAV) vector. To investigate the potential benefits of IL-10 expressing AAV vector-transduced MSCs (IL-10-MSCs), we examined the cell survival rates in the skeletal muscles after intramuscular injection into mice and dogs. Systemic treatment with IL-10-MSCs derived from dental pulp (DPSCs) was comprehensively analyzed using the canine X-linked muscular dystrophy model in Japan (CXMD\(_J\)), which has a severe phenotype similar to that of DMD patients.

Results: In vivo bioluminescence imaging analysis revealed higher retention of IL-10-MSCs injected into the hind-limb muscle of mice. In the muscles of dogs, myofiber-like tissue was formed after the stable engraftment of IL-10-MSCs. Repeated systemic administration of IL-10-DPSCs into the CXMD\(_J\) model resulted in long-term engraftment of cells and slightly increased the serum levels of IL-10. IL-10-hDPSCs showed significantly reduced expression of pro-inflammatory MCP-1 and upregulation of stromal-derived factor-1 (SDF-1). MRI and histopathology of the hDPSC-treated CXMD\(_J\) indicated the regulation of inflammation in the muscles, but not myogenic differentiation from treated cells. hDPSC-treated CXMD\(_J\) showed improved running capability and recovery in tetanic force with concomitant increase in physical activity. Serum creatine kinase levels, which increased immediately after exercise, were suppressed in IL-10-hDPSC-treated CXMD\(_J\).

Conclusions: In case of local injection, IL-10-MSCs could maintain the long-term engraftment status and facilitate associated tissue repair. In case of repeated systemic administration, IL-10-MSCs facilitated the long-term retention of the cells in the skeletal muscle and also protected muscles from physical damage-induced injury, which improved muscle dysfunction in DMD. We can conclude that the local and systemic administration of IL-10-producing MSCs offers potential benefits for DMD therapy through the beneficial paracrine effects of IL-10 involving SDF-1.

Background

Multipotent mesenchymal stromal cells (MSCs) derived from the bone marrow are conventionally termed “adherent non-hematopoietic cells”. The cells express several cell-surface antigenic markers, including CD44, CD73, CD90, and CD105 [1]. MSCs can self-renew and differentiate into several different cell types. These include mesodermal cells, such as osteoblasts, chondrocytes, adipocytes, and myocytes [2-4] as well as non-mesodermal cells, such as hepatocytes [5], neural cells [6], and epithelial cells [7].
The multi-lineage potential of MSCs has been exploited for prospective use in therapies for various diseases. The cells can be easily expanded in culture and are non-tumorigenic. Furthermore, the use of MSCs as third-party materials in cell therapy reflects that MSCs are immune-privileged, unlike other stem cells or induced pluripotent stem cells (iPS), as they do not express human leukocyte antigen (HLA) class II, CD40, CD80, or CD86 molecules [8], and express only low levels of HLA class I. These cells are not lysed by natural killer cells or cytotoxic T lymphocytes [9]. MSCs can influence immune effector cell development, maturation, and function as well as reactive T-cell responses through the production of bioactive cytokines and proteins [10, 11]. The mechanism underlying the immunosuppressive effects of MSCs is unclear. Nonetheless, their immunosuppressive properties have been exploited in clinical applications. MSCs are commercially authorized for the treatment of acute graft-versus-host disease (GVHD). MSCs are attractive candidates for cell-based strategies that target diseases with chronic inflammation, such as Duchenne muscular dystrophy (DMD) [11].

Interleukin-10 (IL-10) is an anti-inflammatory cytokine with anti-apoptotic properties [12] that modulates the inflammatory immune response. IL-10 reduces M1 macrophage activation and inhibits the production of pro-inflammatory cytokines such as interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-a), IL-1b, and IL-6 in inflamed tissues [13, 14]. IL-10 also reduces the expression of CD54, CD80, CD86, and major histocompatibility complex class II molecules, resulting in incomplete T-cell signaling and induction of antigen-specific antibodies. We hypothesized that IL-10 could increase the typically low survival of MSCs by exerting a paracrine effect after transplantation. IL-10-expressing MSCs were previously developed using retroviral [15, 16] and lentiviral vectors [17, 18], and transcription activator-like effector nuclease (TALEN)-mediated gene editing [19]. They were observed to offer therapeutic benefits in collagen-induced inflammatory arthritis [20], and also prevented lung ischemia-reperfusion injury [15], endotoxin-induced acute injury [21], GVHD [16], traumatic brain injury [17], and left ventricular remodeling after myocardial infarction [19].

We developed a continuous IL-10 expression system of MSCs using an adeno-associated virus (AAV) vector. AAV vectors are safe and do not integrate into the host cell genome, and the risk of insertional mutagenesis is low. To investigate the potential benefits of using MSCs for treating muscle disease, we examined whether transduction with the IL-10-expressing AAV vector enhanced the survival rates of MSCs in skeletal muscles, and the potential advantages offered by MSC transplantation. Systemic treatment using MSCs derived from dental pulp (dental pulp stem cells, DPSCs) was comprehensively analyzed using the canine X-linked muscular dystrophy model in Japan (CXMD_{J}), which has a severe phenotype similar to DMD in humans [22, 23]. DPSCs are similar to bone marrow MSCs, which show high expression of the surface markers CD29, CD73, CD90, and CD105, which are common stem cell markers in MSCs, but not CD34 or CD45. We have previously reported that DPSCs also express IL-10 and vascular endothelial growth factor (VEGF) at high levels and exhibit immunosuppressive activities [24, 25]. We evaluated whether DPSCs expressing IL-10 play an important role as a cell source for DMD therapy.
Methods

Animals

NOD/SCID mice were purchased from Nihon CLEA (Tokyo, Japan) and were housed at the National Center of Neurology and Psychiatry (Tokyo, Japan). All experiments using mice were performed in accordance with the guidelines approved by the Nippon Medical School and National Center of Neurology and Psychiatry (NCNP) Animal Ethics Committees. Beagle dogs and CXMD3 colony dogs were maintained according to the NCNP standard protocol for animal care. Experiments were performed in accordance with the guidelines approved by the Ethics Committee for the Treatment of Laboratory Animals at NCNP.

Cell preparation

MSCs derived from rat bone marrow were isolated and expanded as previously described [26]. For the experiments on dogs, healthy donor Beagle dogs were anesthetized using thiopental and isoflurane, and 1.0 mL of bone marrow fluid was collected. The CD271+ MSCs were enriched and cultivated using the MSC Research Tool Box-CD271 (LNGFR) containing CD271 (LNGFR)-PE and anti-PE microbeads for cell separation (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany), as previously reported [27]. Human DPSCs were provided by JCR Pharmaceuticals (Hyogo, Japan). The cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS, Thermo Fisher Scientific) and 1% antibiotic-antimycotic solution (FUJIFILM Wako Pure Chemical Industries, Osaka, Japan) at 37 °C in a 5% CO₂ atmosphere.

Cell culture and gene transduction

To generate luciferase-expressing MSCs, MSCs isolated from Sprague-Dawley rat bone-marrow[26] were transduced with vesicular stomatitis virus-glycoprotein (VSV-G)-pseudotyped retroviral vector encoding firefly luciferase [28]. Canine CD271+ MSCs were transduced with a luciferase-expressing retroviral vector, followed by transduction with enhanced green fluorescent protein (eGFP) or MyoD-expressing adenoviral vector (Ad C2-eGFP or Ad C2-MyoD), as reported previously [27]. To assess the long-term effects of IL-10 expression, MSCs or DPSCs were transduced with AAV1/eGFP or control AAV1/IL-10 vectors developed according to methods described previously [29, 30]. All cells were maintained in DMEM supplemented with 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin (Sigma-Aldrich, St. Louis, MO, USA). For transplantation, the cells were washed with PBS to completely remove the culture medium containing vectors.

Transplantation of MSCs into mice
Luciferase-expressing rat MSCs (Luc-MSCs, $5.0−10.0 \times 10^6$ cells) were injected intramuscularly into the right or left hind-limb muscle of NOD/SCID mice pretreated with cardiotxin (10 µM, Merck KGaA, Darmstadt, Germany) 1 day before the treatment. AAV1/IL-10- or eGFP-vector-transduced Luc-MSCs ($1.0 \times 10^7$ cells, Figure 1) were intramuscularly injected into the right (eGFP-MSCs) and left (IL-10-MSCs) hind-limb muscles of NOD/SCID mice.

**In vivo imaging analysis**

After the injection of luciferase expressing rat-MSCs on day 0 of the experiment, *in vivo* luminescence images were acquired periodically to assess the engraftment efficiency and cell survival in the transplanted mice. Prior to imaging, the mice were anesthetized by inhalation of 2.0% isoflurane and oxygen and injected intraperitoneally with 150 mg luciferin (Summit Pharmaceuticals International Corp., Tokyo, Japan.) per kg body weight. *In vivo* images were acquired using the IVIS charge-coupled-device camera system (Xenogen Corp., Alameda, CA, USA) at multiple time points (0, 3, 7, 18, 27, 31, 34, 42, 49, 54, and 67 days after transplantation). The region of interest (ROI) luminescence signals from individual MSC-injected sites were measured using the Living Image® 3.2 software package (Xenogen Corp.).

**Transplantation into dogs**

AAV1/IL-10-transduced Luc-CD271+ MSCs derived from a healthy dog ($2.4.2.7 \times 10^7$ cells/2 mL) were injected into the muscles of healthy Beagle dogs. Five days before the treatment, muscle degeneration and regeneration cycles were induced in the tibialis anterior (TA) muscles by injecting 10 nmol/kg cardiotxin (C9759, Sigma-Aldrich) under anesthesia. For analgesia treatment, 0.02 mg/kg of buprenorphine hydrochloride (Lepetan, Otsuka Pharmaceutical, Tokyo, Japan) was injected intramuscularly before the effect of general anesthesia wore off. On days 0 and 50 of the experiment, the MSCs were injected into pretreated muscles without using immunosuppressants. The injected muscles were then biopsied at 4 weeks after the treatment, or the animals were sacrificed at 8 weeks after transplantation. The dogs underwent periodic veterinary examinations during the experiments.

hDPSCs or AAV1/IL-10-transduced hDPSCs ($4.0 \times 10^6$ cells/mL/kg body weight at a rate of 1 mL/min) were administered via intravenous injection into CXMDJ that were pretreated with polaramine (chlorpheniramine maleate, 0.15 mg/kg) using nine injections at 2-week intervals (Table 1). After each injection, the activity, heart rate, respiratory rate, and signs of abnormalities were carefully monitored. Weight measurement and blood tests were performed weekly to examine the side effects of repeated cell treatment.

For biopsy and necropsy, the individual muscles were sampled for tendon-to-tendon dissection, divided into several fragments, and immediately frozen in liquid nitrogen-cooled isopentane for
histological analysis. Whole muscle tissue homogenates were prepared using a POLYTRON homogenizer (150–180 min⁻¹) and Multi-Beads Shocker (Yasui Kikai Corp. Osaka, Japan).

**Blood test**

The dogs underwent periodic veterinary examinations at 1-2 week intervals until sampling. Hematological and serum biochemical testing for creatine kinase (CK) was performed using a model F-820 semi-automated hematology analyzer (Sysmex, Hyogo, Japan). The levels of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and blood urea nitrogen (BUN) were determined using a DRI-CHEM3506 automated analyzer (Fuji Film, Tokyo, Japan).

**Histopathological and immunohistochemical analyses**

Samples from MSC-treated TA muscles were collected and immediately frozen in liquid nitrogen-cooled isopentane. Five mice from each group were used for analysis at each time point. Transverse cryosections 8 μm in thickness prepared from the skeletal muscles were stained with H&E using standard procedures. For immunohistochemical analyses, thick cryosections were fixed in acetone for 5 min at −20 °C. The tissue sections were then blocked using 0.5% bovine serum albumin (BSA) in PBS. The following antibodies were used for antigen detection at 1:40–1:50 dilutions: rabbit anti-firefly luciferase (ab21176; Abcam Plc., Cambridge, UK) and mouse anti-dystrophin (NCL-DYS3, Leica, Wetzlar, Germany). These antibodies were diluted using 0.5% BSA in PBS and used to treat the cells or tissue sections overnight at 4 °C. The tissue sections were washed with PBS and then probed with Alexa 568-conjugated anti-rabbit IgG antibodies (Thermo Fisher Scientific) and Alexa 488-conjugated anti-mouse IgG antibodies (Thermo Fisher Scientific) at 1:250–1:100 dilution for 1 h at 4 °C. The coverslip slides were washed with PBS and mounted in Vectashield (Vector Laboratories Inc., Burlingame, CA, USA) with 4,6 -diamidino-2-phenylindole (DAPI). Immunofluorescence analysis was performed using an IX71 fluorescence microscope (Olympus, Tokyo, Japan).

To confirm the presence of transplanted cells at the injection sites, the MSCs were labeled with luciferase or eGFP. The tissue sections were incubated in a solution of 3% H₂O₂ to block endogenous peroxidase. The nonspecific binding sites were blocked using a 2% BSA solution. The tissue sections were probed with primary antibodies for 1 h and then treated using the 3,3'-diaminobenzidine (DAB) substrate kit (Vector Laboratories Inc.) containing horseradish peroxidase (HRP) as an enzyme indicator. The slices were then stained with DAB chromogen to determine the form of the brown-antigen reaction product. The tissue sections were visualized using an IX71 microscope (Olympus).

**ELISA**
The IL-10 expression levels were measured in the FBS-free MSC culture medium after 2 days of incubation, in the TA muscle lysate, and in the serum obtained from animals using the Quantikine ELISA mouse or canine IL-10 Immunoassay (Thermo Fisher Scientific) and canine IL-6 (R&D Systems Inc.) and the collagen type III Immunoassay (Cloud-clone Corp. TX, USA), according to the manufacturers’ recommendations. The final values were normalized to the protein concentrations, which were measured using the Pierce® BCA Protein Assay Kit (Thermo Fisher Scientific).

**Luciferase reporter assays**

Luciferase reporter assays were performed to evaluate the retention of Luc-MSCs in the TA muscle. Firefly luciferase activity was tested in whole tissue homogenates using the Bright-Glo™ Luciferase Assay System (Promega Corporation, Madison, WI) according to the manufacturer’s instructions. Luciferase levels were measured using a Varioskan LUX Multimode Microplate Reader (Thermo Fisher Scientific). Protein concentrations were measured using a Pierce® BCA Protein Assay Kit (Thermo Fisher Scientific, Rockford, IL, USA). Three independent experiments were performed in duplicate.

**Biodistribution of MSCs**

The tissue samples were disrupted in a Multi-Beads Shocker (Yasui Kikai Co., Ltd., Osaka, Japan). DNA was extracted from the tissue suspensions using a DNeasy Blood and Tissue kit (QIAGEN, Valencia, CA) and quantified using a NanoDrop spectrophotometer (Thermo Fisher Scientific). Real-time qPCR was performed using 125 ng of DNA in a total volume (20 µL) containing DNA Master SYBR Green I kit (Roche Diagnostics, Basel, Switzerland) and primers for *Alu* or murine glyceraldehyde 3-phosphate dehydrogenase (*Gapdh*). The primer sequences used were as follows: human *Alu*, 5'-GTAGGAGATCGAGACCATCCC-3' (forward) and 5'-TCCTGCCTCACGCTTCCAAG-3' (reverse); murine *Gapdh*, 5'-GATGACATCAAGAAGGTGGTGA-3' (forward) and 5'-TGCTGTAGCCGTATTGTC-3' (reverse). The PCR conditions were as follows: 95 °C for 2 min, followed by 40 cycles at 95 °C for 15 s, 68 °C for 30 s, and 72 °C for 30 s. The standard was generated by adding 10-fold serial dilutions of human DPSCs to determine the number of human DPSCs in 125 ng of DNA that was used in the real-time PCR for each organ sample. We extrapolated the quantity of DNA isolated from each organ to determine the number of human DPSCs per organ.

**Proteome cytokine/cytokine array**

The FBS-free DPSC culture medium was collected after 2 days of incubation for array analysis. The relative expression of cytokines and chemokines in the culture medium was quantified using the Proteome Profiler™ Array (Mouse Cytokine Array, Panel A; R&D Systems Inc.), as previously described.
To achieve maximum assay sensitivity, the blots were incubated overnight with plasma. Enhanced chemiluminescence incubation was performed for 5 min using the Super Signal West Femto Chemiluminescence Kit (Thermo Scientific Pierce), and the samples were imaged and analyzed using the Image Quant LAS 4000 coupled with Image Quant TL software (GE Healthcare Japan, Tokyo, Japan) and Image J software (NIH, Bethesda, MD).

**Locomotor activity analyses**

The physical activity levels of CXMD<sub>J</sub> and littermate normal dogs used as controls were monitored during the experimental period using an infrared sensor system (Supermex, Muromachi Kikai Co., Ltd., Tokyo, Japan), as previously described [31]. These systems monitor and enumerate all spontaneous movements. The average of all counts of spontaneous locomotor activity in animals determined over 5 days and nights (12 h light/dark cycles) was calculated. Furthermore, we measured the 15-m running time of normal and CXMD<sub>J</sub> littermates during the experimental period. The running speed was averaged four times.

**Magnetic resonance imaging (MRI)**

CXMD<sub>J</sub> anesthetized by injection (20 mg/kg) were intubated using an endotracheal tube, and general anesthetization was maintained using an inhalational mixture of 2% to 3% isoflurane and oxygen. The heart rate and oxygen saturation levels were monitored continuously. Images of the T2-weighted and fat-saturated T2-weighted series were captured using a method described in a previous study [32]. We examined the crus muscles of the lower limbs using a superconducting 3.0-Tesla MRI device (MAGNETOM Trio; Siemens Medical Solutions, Erlanger, Germany) with an 18-cm diameter/18-cm length human extremity coil. The images were analyzed quantitatively using the Syngo MR2004A software (Siemens Medical Solutions), as previously reported [32, 33]. Briefly, the ROIs were selected to avoid flow artifacts and large vessels, and the signal intensities were measured for these ROIs. The SNRs for each ROI were calculated using the following equation: SNR = signal intensity/SDair, where SDair is the standard deviation (SD) of the background noise. The average SNR (Ave SNR) was calculated using the equation described in a previous report [33]. The right and left TA muscles, EDL, gastrocnemius medial head, GL, flexor digitorum superficialis, flexor digitorum longus, and flexor hallucis longus muscle were examined.

**Statistical analyses**

Data are presented as the mean ± SD. Differences between two groups were assessed using unpaired two-tailed t-tests. Multiple comparisons between three or more groups were performed using ANOVA (n = 3–6). Statistical significance was defined as *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, and was calculated using Microsoft Excel (Microsoft, Redmond, WA, USA) and GraphPad Prism 8 (GraphPad, La Jolla, CA, USA).
Results

Enhanced engraftment of IL-10-expressing MSCs

We investigated the effects of IL-10 after MSC injection into the skeletal muscle. In vivo bioluminescence imaging analysis showed that IL-10-expressing MSCs tended to exhibit higher retention in the hind limb muscle of NOD/SCID mice than normal MSCs 4 days after injection; however, upon quantitative analysis, the difference was not found to be significant (Figures S1A, B). When luciferase (Luc)-MSCs were injected along with AAV1/IL-10 or AAV1/LacZ control vectors, which were also not transduced into the cells, a significant difference was observed in cell survival in the Luc-MSC-treated mice (Figures S1C, D). IL-10 plasmid-transfected Luc-MSCs expressed higher levels of IL-10 and were more effective at enhancing post-transplantation retention. We also confirmed a maximum 5.03-fold stronger luciferase signal intensity in muscles transplanted with IL-10-expressing MSCs than in control MSC-treated muscles at day 7 (See also Figure S2), although most of these cells disappeared within 12 days. We developed a continuous IL-10 expression system of MSCs using an AAV vector to confirm the expected high and prolonged cell survival rates following transplantation. The IL-10-Luc-MSCs displayed a higher survival rate immediately after administration (luciferase signal at 3 days after transplantation, $4.41 \pm 1.78 \times 10^5$ counts), with the maximum value of 6.5-fold observed at 24 days ($3.46 \pm 1.12 \times 10^4$ counts) compared to the signal corresponding to GFP-Luc-MSCs ($2.98 \pm 1.04 \times 10^5$ counts, $P < 0.0001$; $5.35 \pm 2.93 \times 10^3$ counts, $< 0.005$, respectively), as observed in vivo in imaging (Figure 1A, B) and immunohistological analyses (Figure S3). Significantly higher levels of IL-10 expression from AAV1/IL-10-transduced Luc-MSCs (IL-10-Luc-MSCs) were confirmed in vitro (Figure 1C) and in treated muscles (See also Figure S4). The findings suggested that the higher retention in the early stage exerted a significant effect on long-term engraftment. Notably, IL-10-Luc-MSCs were retained for more than 67 days after transplantation (Figure 1A, B).

Successful long-term engraftment of IL-10-MSCs in injured muscle tissue

We also investigated the effects of IL-10 overexpression in CD271+MSCs derived from dog bone marrow using Beagle dogs as a larger animal model (Figure 2A, Table 1). The high efficiency of adenovirus and AAV1 transduction in CD271+MSCs was confirmed based on immunofluorescence analysis or GFP signals (See also Figure S5). CD271+MSCs transduced with AAV1/IL-10 (IL-10-Luc-CD271+MSCs) exhibited IL-10 overexpression in the culture medium (MyoD-MSCs, 3.1 pg/mL; IL-10-MSCs, 93.6 pg/mL). Four weeks after intramuscular injection, the accumulation of IL-10-Luc-CD271+MSCs was observed in the immunochemical analysis of cardiotoxin-injured tibialis anterior (TA) muscle tissues. Immunofluorescence analysis revealed the accumulation of luciferase-positive IL-10-Luc-CD271+MSCs around the inflammatory region in MSC-treated TA muscle 4 weeks after the secondary injection, comparable to the observation for MyoD-MSCs (Figure 2B). Luciferase-positive muscle-like tissue was detected in the IL-10-Luc-CD271+MSC-treated muscle, similar to that observed in the muscle after
treatment with Luc-CD271+ MSCs transduced with MyoD (MyoD-Luc-CD271+MSC), which is a key factor for myogenic determination, as described in a previous report [27]. These findings suggest that the Luc-CD271+MSCs transduced with AAV1/IL-10 formed myofibers. Luciferase activity, which correlated with the number of MSCs, tended to be higher in IL-10-Luc-CD271+MSC-treated whole TA muscles than in MyoD-Luc-CD271+MSC-treated muscle (Figure 2C). The IL-10 levels in IL-10-Luc-CD271+MSC-treated TA muscles increased, while those in MyoD- Luc-CD271+MSC-treated muscles did not (Figure 2D). These data suggest that IL-10-expressing CD271+MSCs could survive long-term and engraft after intramuscular injection during muscle regeneration.

Safety and efficacy of systemic transplantation of IL-10-DPSCs in the DMD model

Next, we evaluated the efficacy of IL-10-expressing MSCs by performing systemic transplantation using hDPSCs (Figure 3A). We confirmed that the extracellular secretion of IL-10 from AAV1/IL-10-transduced-human DPSCs (IL-10-hDPSCs) significantly inhibited the expression of pro-inflammatory monocyte chemotactic protein-1 (MCP-1), and conversely upregulated stromal-derived factor-1 (SDF-1) in IL-10-hDPSCs compared with the levels observed in hDPSCs (Figures 3B, C). IL-10-hDPSCs or hDPSCs were intravenously injected nine times at biweekly intervals in the acute phase in the CXMD model with the DMD phenotype (Table 1). No obvious abnormalities related to liver damage, kidney damage, or anemia were induced in response to the systemic administration of hDPSCs in the CXMD model. Transient increases in ALT, AST, and BUN levels were observed occasionally in the CXMD model, independent of treatment with hDPSCs (See also Figure S6). During the experiment, the IL-10-hDPSC-treated CXMD showed better growth compared to the untreated littermates, CXMD (< 0.0001), and hDPSC-treated CXMD (< 0.0001), in terms of body weight (Figure 3D). Although the serum levels of IL-10 increased transiently 6 h after IL-10-hDPSC injection (104.0 pg/mL vs. control DMD, vs. hDPSC-DMD, < 0.0001), the levels decreased rapidly within 24 h of transplantation (32.6 pg/mL vs. control DMD, < 0.0067; vs. hDPSC-DMD, < 0.0278), and did not differ significantly from the control CXMD 7 days after injection (21.6 pg/mL) (Figure 3E). The levels of IL-6 in blood increased transiently in CXMD (maximum 742.9 pg/mL). In contrast, the levels in IL-10-hDPSC-treated CXMD were within the normal range (0–9.85 pg/mL) during the experiments. High levels of IFN-g were also observed in CXMD (maximum 103.9 pg/mL) and hDPSC-treated CXMD (114.8 pg/mL), whereas the levels tended to be marginally lower in the IL-10-hDPSC-treated CXMD (68.4 pg/mL). The trend of cell retention in blood was similar for hDPSCs (17.9 ± 19.5 pg/100 ng genomic DNA) and IL-10-hDPSCs 24 h after transplantation (79.4 ± 7.89 pg/100 ng genomic DNA), as revealed by human-specific Alu-PCR. Long-term engraftment in tissues was investigated. hDPSCs were not detected in the skeletal muscle, lung, or liver tissues of the hDPSC-treated CXMD. The IL-10-hDPSCs only survived and maintained the engraftment status 4 months after treatment in the TA muscle (56.1 pg/100 ng genomic DNA), whereas the cells were not detected in other organs. Conversely, dystrophin expression was undetectable in the muscle tissues of hDPSC-treated CXMD (Figure S7A).
**Morphological improvement in IL-10-hDPSC-treated dog with DMD**

The high-intensity T2-signals observed in MRI, which were detected in the necrotic/edematous and inflammatory lesions in the dystrophic muscle, were significantly reduced in the cross-sectional muscles of the IL-10-hDPSC-treated dog (82.5 ± 16.9 average signal-to-noise ratios, SNRs) compared to the signals in hDPSC-treated CXMD\(_J\) (97.4 ± 13.3, \(P = 0.008\)) after transplantation (Figure 4A, B). The weight of each muscle obtained from IL-10-hDPSC-treated CXMD\(_J\) (3.73 ± 1.43 g) increased compared to that in the untreated (2.16 ± 1.04 g, vs. IL-10-hDPSC- CXMD\(_J\), < 0.005) and hDPSC-treated CXMD\(_J\) (2.33 ± 1.04 g, < 0.005) (Figure 4C). We also confirmed that the area of the muscle fiber in the extensor digitorum longus (EDL) muscle from IL-10-hDPSC-treated CXMD\(_J\) (935.7 ± 601.9 µm\(^2\)) increased compared to that in the untreated (537.6 ± 439.2 µm\(^2\) vs. IL-10-hDPSC- CXMD\(_J\), < 0.0001) and hDPSC-treated CXMD\(_J\) (629.3 ± 352.8 µm\(^2\), < 0.0001) (Figure 4D). The gastrocnemius lateral (GL), EDL, and flexor digitorum superficialis (FDS) muscles from CXMD\(_J\) displayed smaller (regenerating fibers) and larger (hypertrophic fibers) fiber diameter in the dystrophic muscles, spread muscle interstitium, and cell infiltration interspersed in the muscle interstitium (Figure 4E). In contrast, the histopathological observations of the hDPSC- and IL-10-hDPSC-treated CXMD\(_J\) muscles revealed significantly limited infiltration of nuclei, which indicated a milder phenotype compared to untreated CXMD\(_J\). These data suggest that the repeated systemic administration of IL-10-hDPSCs induces morphological improvement, including inflammation regulation, in CXMD\(_J\). In addition, we performed quantitative analysis of collagen-3 expression at 8 muscle tissue sites to investigate fibrosis. However, we could not confirm a significant difference among the groups (control-DMD, 2.27 ± 2.18 pg/µg protein; hDPSC- and IL-10-hDPSC-DMD, 3.91 ± 1.66, and 6.17 ± 2.50 pg/µg protein, respectively, \(P = 0.317\)).

**Long-term maintenance of muscle function in IL-10-hDPSC-treated DMD dog**

The CXMD\(_J\) developed progressive general weakness owing to the reduced strength of the skeletal muscles. The tetanic force in the hind limbs in CXMD\(_J\) (2.55 ± 0.42 N·m/s) was 41.2 ± 5.1% of that in normal dogs (\(P < 0.0001\)) (Figure S8). Conversely, significantly higher torque values were observed in the IL-10-hDPSC-treated CXMD\(_J\) (4.17 ± 1.28 N·m/s, 66.5 ± 12.2% of the value in the normal dog, < 0.0001) than in CXMD\(_J\) (< 0.0008), similar to that in hDPSC-treated CXMD\(_J\) (3.68 ± 0.57 N·m/s). These results suggest that the progressive loss of limb muscle strength is ameliorated upon treatment with hDPSCs and IL-10-hDPSCs.

Additionally, the physical activity of CXMD\(_J\) in the home cage also reduced drastically with age compared to that in normal dogs (Figure 5A) [31]. Improved activity was confirmed in both groups, the hDPSC-treated (8340.4 ± 1090.3 counts; vs. control DMD, \(P = 0.0006\)) and IL-10-hDPSC-treated CXMD\(_J\) (8531.6 ±
1146.5 counts; vs. control DMD, < 0.0001), which was observed upon the comparison with one-year-old CXMD\(_J\) littermates advanced symptoms (3954.4 ± 792.0 counts) (Figure 5A). The IL-10-hDPSC-treated CXMD\(_J\) exhibited persistent and predominantly higher activity (6 months; 13008.8 ± 1367.1 counts) than CXMD\(_J\) (9926.0 ± 1436.8 counts, < 0.005) as well as hDPSC-treated CXMD\(_J\) (12605.8 ± 1756.3 counts). Furthermore, hDPSC- or IL-10-hDPSC-treated CXMD\(_J\) maintained a 15-m running speed, and were active at 3 to 12 months of age (Figure 5B, see also Figure S9, and Table S1; normal vs. control DMD, \(P < 0.0001−0.0062\); control DMD vs. hDPSC-DMD, < 0.005; control DMD vs. IL-10-hDPSC-DMD, < 0.005). There was no significant difference in the running speed between hDPSC- and IL-10-hDPSC-treated CXMD\(_J\). However, the increased serum CK levels after running exercise (50595 ± 67255 unit/L) were restored immediately until 20 min in IL-10-hDPSC-treated CXMD\(_J\) (Figure 5C, 16490 ± 4850 unit/L; vs. hDPSC-treated DMD, \(P = 0.0134\)). Conversely, a persistent and significant increase in the serum CK levels was observed in hDPSC-treated CXMD\(_J\) (0 min, 96075 ± 24311 unit/L; 20 min, 95300 ± 16835 unit/L) as well as in the untreated CXMD\(_J\) (0 min, 76650 ± 46995 unit/L; 20 min, 81425 ± 47458 unit/L, \(P = 0.9277\)) after exercise. CXMD\(_J\) also showed higher concentrations of lactic acid before and after exercise compared to normal dogs. However, no significant change in the levels of lactic acid was observed in hDPSC-treated CXMD\(_J\) (Figure 5D). These findings suggest that IL-10-hDPSCs exert a protective effect against dystrophic damage caused by exercise.

Overall, we observed that IL-10-expressing hDPSCs were able to ameliorate the dystrophic phenotype upon systemic repeated administration in dogs with DMD.

**Discussion**

To improve the functionality of MSCs as a cell source, we focused on the overexpression of IL-10 based on its anti-apoptotic and anti-inflammatory properties. In this study, bone marrow MSCs derived from rat and CD271\(^+\) MSCs isolated from healthy dogs were injected intramuscularly into NOD/SCID mice or healthy Beagle dogs to study cell survival and engraftment in injured muscles (Figure 1 and 2). hDPSCs exhibit cellular properties that are highly similar to those of bone marrow MSCs. Human-origin DPSCs or IL-10-transduced hDPSCs were also administered via intravenous injection into CXMD\(_J\) to investigate their systemic therapeutic effects (Figure 3-5). Our results indicate an improvement in survival rate, engraftment, and protective effects of different types of MSC in muscle tissues. This property is considered to be highly common to MSCs.

The higher survival rate of IL-10-MSCs in the early stage immediately after transplantation, as observed in the *in vivo* imaging analysis, is thought to facilitate long-term cell retention (Figure 1), suggesting that stable IL-10 expression enabled the long-term survival and engraftment of MSCs after transplantation. Our findings suggest that during skeletal muscle regeneration, prolonged engraftment of IL-10-expressing CD271\(^+\)MSCs eased the formation of new myofiber-like tissue and preservation of a functional contractile apparatus, following exposure to the muscle stem cell niche/microenvironment (Figure 2). Rarely, MSCs differentiate into myogenic lineage cells in the absence of triggers such as MyoD (See also...
Although we could not confirm the myogenic differentiation of IL-10-MSCs in this study, as shown in Figure S7B, IL-10 is also considered to play a role in the long-term engraftment and survival of MSCs in muscle tissue, resulting from their association with surrounding myogenic stem/progenitor cell populations, such as satellite cells, skeletal muscle-MSCs, and fibro-adipogenic progenitors (FAB) for muscle repair. Furthermore, treatment of myocardial infarction with CD271+ bone-marrow MSCs inhibited the expression of inflammatory cytokines and significantly upregulated pro-angiogenic VEGF [36]. CD271+ MSCs expressing IL-10 are also thought to enhance pro-angiogenic differentiation in injured tissue as a result of prolonged survival.

It was reasoned that IL-10-expressing hDPSCs exerted enhanced anti-inflammatory and protective effects on damaged tissue owing to the downregulation of MCP-1 and upregulation of SDF-1 in IL-10-hDPSCs (Figure 3). SDF-1 is a crucial factor that supports tissue regeneration, and the roles of SDF-1 in MSC paracrine-mediated tissue repair have been reported [37]. Furthermore, it was also reported that the expression of multiple pro-angiogenic factors, such as SDF-1, FGF-2, IGF-1, and VEGF-A, is upregulated in IL-10-MSC-treated cardiac-muscle [19], suggesting changes in the surrounding microenvironment.

In the dog model, the repeated systemic transplantation of hDPSCs and IL-10-expressing hDPSCs was safe and effective as a strategy for DMD therapy, as indicated by the blood tests, growth, spontaneous activity, and running function (Figures 3 and 4). Long-term engraftment of hDPSCs was only confirmed in the dystrophic muscles in IL-10-DPSC-treated DMD, which suggests that hDPSC engraftment was enhanced in response to IL-10 paracrine effects. For example, SDF-1 and growth factors might enhance DPSC retention by altering the microenvironment. SDF-1 and its receptor CXCR4 and CXCR7, stimulate the production of paracrine mediators, including VEGF, β-FGF-1, and HGF, which exert anti-apoptotic, pro-angiogenic, and anti-inflammatory effects [38]. In addition, it is revealed that muscle regeneration is associated with muscular re-expression of CXCR4 in dystrophic muscle [39]. Based on this, we consider that IL-10-DPSC specific engraftment and therapeutic effects may be associated with DMD treatment.

These facts provide evidence of the accumulation of hDPSCs at the site of inflammation after systemic administration, similar to that of MSCs. The functional recovery in the dystrophic skeletal muscles was attributed to the alleviation of the morphological pathologies, as indicated by the MRI findings and the histopathological appearance of samples from the hDPSC- and IL-10-hDPSC-treated CXMDJ; however, fibrosis was not prevented (Figure 4). Indeed, both hDPSC- and IL-10-hDPSC-treated CXMDJ showed improved limb strength, as evidenced by the tetanic force, revealing an improvement in spontaneous activity and running speed, while no significant difference was observed in the treated CXMDJ while maintaining apparent function. We observed that the IL-10-hDPSC-treated CXMDJ was more stable than the hDPSC-treated CXMDJ because the increase in serum CK levels after exercise was rapidly stabilized in the IL-10-hDPSC-treated CXMDJ (Figure 5C). These facts suggest that treatment with IL-10-hDPSCs provides protection from physical damage-induced muscle injury in CXMDJ, as opposed to the effect observed in dogs injected with untreated or non-transgenic cells, which is further evidenced by the effects of the modified characteristics of IL-10-hDPSCs involved in SDF-1 and VEGF. However, it was not clear
whether the protective effects of IL-10-hDPSCs on the dystrophic muscle were caused by IL-10 directly or indirectly. The molecular mechanisms underlying the action of IL-10-hDPSCs are expected to be elucidated in future studies.

This is the first report of increased cell survival, engraftment, and possible tissue formation induced by IL-10-secreting MSCs in muscle tissues. In our previous report, myogenic lineage-MSCs were successfully engrafted in muscle tissues [27]. However, a more efficient transplantation strategy is required for functional improvement of muscle dystrophy. This study evaluated the possibility of improving survival, engraftment, and immune-modulation of MSCs by AAV vector-mediated stable expression of IL-10.

We have previously provided evidence that severe phenotypes in IL-10 knockout mdx mice, such as increased M1-macrophage infiltration, high inflammatory factor levels, and progressive cardiorespiratory dysfunction, show a predisposition toward inflammation [40]. Glucocorticoids are widely used in patients to interrupt and improve muscle strength during early stages, which may also act directly on muscle fibers by stabilizing sarcolemma [41, 42]; however, this method is frequently associated with severe side effects. In our strategy, MSCs appeared to exhibit inflammatory regulation effects and a protective effect in the dystrophic muscle through the suppression of M1-macrophage infiltration by secreting IL-10. In addition, our stable IL-10 expression system was found to be safe, with a low risk of genome insertion owing to the use of an AAV vector. Random integration, off-target effects, and poor specificity are associated with the use of other viruses and genome engineering techniques. IL-10-expressing MSCs are expected to have potential applicability in muscle regeneration and treatment of muscle diseases. We have previously reported that IL-10 overexpression promotes neuroprotection in an experimental acute ischemic stroke model [43]. There is clinical interest in the applicability of IL-10-MSCs in ex vivo cell therapy owing to their anti-inflammatory properties and ability to release cytokines into the surrounding environment, which mediate their paracrine effects and modify the developmental fate of neighboring cells. We expect that the multiple characteristics and regenerative effects of MSCs alone as well as in combination with CD271+ IL-10 MSCs will result in an improved therapeutic impact in DMD.

**Conclusions**

Our methods were developed to enhance MSC survival and improve their therapeutic effects using the anti-inflammatory properties of IL-10 in DMD treatment. In case of local injection, the IL-10-MSCs could maintain the long-term engraftment status and facilitate associated tissue repair. In case of repeated systemic administration, the IL-10-MSCs also protected the muscles from physical damage-induced injury, which improved the signs of muscle dysfunction in DMD. We can conclude that the local and systemic administration of IL-10-MSCs may exert beneficial IL-10 paracrine effects, which have potential value in DMD therapeutics.

**Abbreviations**
AAV: Adeno-associated virus
ALT: Alanine aminotransferase
BSA: Bovine serum albumin
BUN: Blood urea nitrogen
CD: Cluster of differentiation
CK: Creatine kinase
CXMD\textsubscript{J}: Canine X-linked muscular dystrophy model in Japan
DAB: 3,3'-diaminobenzidine
DAPI: 4',6'-diamidino-2-phenylindole
DMD: Duchenne muscular dystrophy
DMEM: Dulbecco's Modified Eagle Medium
DPSCs: Dental pulp stem cells
eGFP: Enhanced green fluorescent protein
EDL: Extensor digitorum longus
FAB: Fibro-adipogenic progenitors
FBS: Fetal bovine serum
FDS: Flexor digitorum superficialis
GAPDH: Glyceraldehyde 3-phosphate dehydrogenase
GL: Gastrocnemius lateral
GVHD: Graft-versus-host disease
HLA: Human leukocyte antigen
HRP: Horseradish peroxidase
IFN-g: Interferon-gamma
IL-10: Interleukin-10
Declarations

Ethics approval and consent to participate

Animal experiments using MSCs were conducted in accordance with the protocol approved by the Institutional Animal Care and Use Committee of Nippon Medical School (27-199) and National Center of Neurology and Psychiatry (NCNP) Animal Ethics Committees (2012011, 2015004, and 19–30-06).

Consent for publication

Not applicable.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

Y. N-K., T. O., and S.T. have patent applications related to MSCs expressing IL-10. H. H-K., Y. N-K. and T. O. were members of the Division of Cell and Gene Therapy, Nippon Medical School, which is an endowment department, supported with a grant from JCR Pharmaceuticals Co., Ltd and Kaneka Corporation

Funding

This work was supported by a research grant from JCR Pharmaceuticals Co., Ltd., Health Sciences Research Grants for Research on Human Genome and Gene Therapy from the Ministry of Health, Labor and Welfare of Japan, and a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (grant number: 22390284, 22-40134).

Authors’ contributions

Y. N-K. and T. O. conceived and planned the experiments. Y. N-K. and M.K. performed the experiments, derived the models, and analyzed the data. H. H-K. Y.O. and M.K. contributed to sample preparation and assisted with experiments involving animal models. Y. N-K. wrote the manuscript in consultation, and T.O. and S.T. helped supervise the project. T.O. supervised the project.

Acknowledgments

The authors express their gratitude to Akihiko Umezawa, Akinori Nakamura, Tetsuya Nagata, Masanori Kobayashi, Yuko Shimizu-Motohashi, Jun Tanihata, Michihiro Imamura, and Kazuhiro Yamamoto for their technical advice, support, and helpful discussions; Tomoko Chiyo, Chiaki Masuda, Kazue Kinoshita, Ryoko Nakagawa, and Rie Ogawa for technical assistance; Hideki Kita, Shinichi Ichikawa, Yumiko Yahata-Kobayashi, Aya Kuriyama, Akane Hanaoka-Hayashi, Namiko Ogawa, and other staff members of JAC Co. for caring for the dogs (General Animal Research Facility, NCNP). We are thankful to JCR Pharmaceuticals Co., Ltd. for their generous contribution of DPSCs and MSCs. We also thank Posadas Herrera Guillermo for checking the quality of English in the manuscript.

References
1. Friedenstein AJ, Petrakova KV, Kurolesova AI, and Frolova GP: Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. *Transplantation*. 1968, 6: 230-247.

2. Bruder SP, Jaiswal N, and Haynesworth SE: Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. *J Cell Biochem*. 1997, 64: 278-294.

3. Haynesworth SE, Goshima J, Goldberg VM, and Caplan AI: Characterization of cells with osteogenic potential from human marrow. *Bone*. 1992, 13: 81-88.

4. Dezawa M, Ishikawa H, Itokazu Y, Yoshihara T, Hoshino M, Takeda S, Ide C, and Nabeshima Y: Bone marrow stromal cells generate muscle cells and repair muscle degeneration. *Science*. 2005, 309: 314-317.

5. Sun Y, Liu J, Qian F, and Xu Q: Nitric oxide inhibits T cell adhesion and migration by down-regulation of beta1-integrin expression in immunologically liver-injured mice. *Int Immunopharmacol*. 2006, 6: 616-626.

6. Kopen GC, Prockop DJ, and Phinney DG: Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. *Proc Natl Acad Sci U S A*. 1999, 96: 10711-10716.

7. Ma Y, Xu Y, Xiao Z, Yang W, Zhang C, Song E, Du Y, and Li L: Reconstruction of chemically burned rat corneal surface by bone marrow-derived human mesenchymal stem cells. *Stem Cells*. 2006, 24: 315-321.

8. Nauta AJ, and Fibbe WE: Immunomodulatory properties of mesenchymal stromal cells. *Blood*. 2007, 110: 3499-3506.

9. Rasmusson I, Ringden O, Sundberg B, and Le Blanc K: Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. *Transplantation*. 2003, 76: 1208-1213.

10. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, Giunti D, Ceravolo A, Cazzanti F, Frassoni F, Mancardi G, and Uccelli A: Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. *Blood*. 2005, 106: 1755-1761.

11. Ichim TE, Alexandrescu DT, Solano F, Lara F, Campion Rde N, Paris E, Woods EJ, Murphy MP, Dasanu CA, Patel AN, Marleau AM, Leal A, and Riordan NH: Mesenchymal stem cells as anti-inflammatory: implications for treatment of Duchenne muscular dystrophy. *Cell Immunol*. 2010, 260: 75-82.

12. Aggarwal S, and Pittenger MF: Human mesenchymal stem cells modulate allogeneic immune cell responses. *Blood*. 2005, 105: 1815-1822.

13. MacDonald KP, Pettit AR, Quinn C, Thomas GJ, and Thomas R: Resistance of rheumatoid synovial dendritic cells to the immunosuppressive effects of IL-10. *J Immunol*. 1999, 163: 5599-5607.

14. Groux H, Bigler M, de Vries JE, and Roncarolo MG: Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. *J Immunol*. 1998, 160: 3188-3193.

15. Manning E, Pham S, Li S, Vazquez-Padron RI, Mathew J, Ruiz P, and Salgar SK: Interleukin-10 delivery via mesenchymal stem cells: a novel gene therapy approach to prevent lung ischemia-reperfusion
16. Min CK, Kim BG, Park G, Cho B, and Oh IH: **IL-10-transduced bone marrow mesenchymal stem cells can attenuate the severity of acute graft-versus-host disease after experimental allogeneic stem cell transplantation.** Bone Marrow Transplant. 2007, **39**: 637-645.

17. Peruzzaro ST, Andrews MMM, Al-Gharaibeh A, Pupiec O, Resk M, Story D, Maiti P, Rossignol J, and Dunbar GL: **Transplantation of mesenchymal stem cells genetically engineered to overexpress interleukin-10 promotes alternative inflammatory response in rat model of traumatic brain injury.** J Neuroinflammation. 2019, **16**: 2.

18. Lu X, Ru Y, Chu C, Lv Y, Gao Y, Jia Z, Huang Y, Zhang Y, and Zhao S: **Lentivirus-mediated IL-10-expressing Bone Marrow Mesenchymal Stem Cells promote corneal allograft survival via upregulating IncRNA 003946 in a rat model of corneal allograft rejection.** Theranostics. 2020, **10**: 8446-8467.

19. Meng D, Han S, Jeong IS, and Kim SW: **Interleukin 10-Secreting MSCs via TALEN-Mediated Gene Editing Attenuates Left Ventricular Remodeling after Myocardial Infarction.** Cell Physiol Biochem. 2019, **52**: 728-741.

20. Choi JJ, Yoo SA, Park SJ, Kang YJ, Kim WU, Oh IH, and Cho CS: **Mesenchymal stem cells overexpressing interleukin-10 attenuate collagen-induced arthritis in mice.** Clin Exp Immunol. 2008, **153**: 269-276.

21. Wang C, Lv D, Zhang X, Ni ZA, Sun X, and Zhu C: **Interleukin-10-Overexpressing Mesenchymal Stromal Cells Induce a Series of Regulatory Effects in the Inflammatory System and Promote the Survival of Endotoxin-Induced Acute Lung Injury in Mice Model.** DNA Cell Biol. 2018, **37**: 53-61.

22. Shimatsu Y, Yoshimura M, Yuasa K, Urasawa N, Tomohiro M, Nakura M, Tanigawa M, Nakamura A, and Takeda S: **Major clinical and histopathological characteristics of canine X-linked muscular dystrophy in Japan, CXMDJ.** Acta Myol. 2005, **24**: 145-154.

23. Shimatsu Y, Katagiri K, Furuta T, Nakura M, Tanioka Y, Yuasa K, Tomohiro M, Kornegay JN, Nonaka I, and Takeda S: **Canine X-linked muscular dystrophy in Japan (CXMDJ).** Exp Anim. 2003, **52**: 93-97.

24. Jo YY, Lee HJ, Kook SY, Choung HW, Park JY, Chung JH, Choung YH, Kim ES, Yang HC, and Choung PH: **Isolation and characterization of postnatal stem cells from human dental tissues.** Tissue Eng. 2007, **13**: 767-773.

25. Nito C, Sowa K, Nakajima M, Sakamoto Y, Suda S, Nishiyama Y, Nakamura-Takahashi A, Nitahara-Kasahara Y, Ueda M, Okada T, and Kimura K: **Transplantation of human dental pulp stem cells ameliorates brain damage following acute cerebral ischemia.** Biomed Pharmacother. 2018, **108**: 1005-1014.

26. Uchibori R, Okada T, Ito T, Urabe M, Mizukami H, Kume A, and Ozawa K: **Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy.** J Gene Med. 2009, **11**: 373-381.

27. Nitahara-Kasahara Y, Hayashita-Kinoh H, Ohshima-Hosoyama S, Okada H, Wada-Maeda M, Nakamura A, Okada T, and Takeda S: **Long-term engraftment of multipotent mesenchymal stromal...**
cells that differentiate to form myogenic cells in dogs with Duchenne muscular dystrophy. *Mol Ther.* 2012, **20**: 168-177.

28. Nitahara-Kasahara Y, Hayashita-Kinoh H, Chiyo T, Nishiyama A, Okada H, Takeda S, and Okada T: *Dystrophic mdx mice develop severe cardiac and respiratory dysfunction following genetic ablation of the anti-inflammatory cytokine IL-10.* *Hum Mol Genet.* 2014, **23**: 3990-4000.

29. Okada T, Nomoto T, Yoshioka T, Nonaka-Sarukawa M, Ito T, Ogura T, Iwata-Okada M, Uchibori R, Shimazaki K, Mizukami H, Kume A, and Ozawa K: *Large-scale production of recombinant viruses by use of a large culture vessel with active gassing.* *Hum Gene Ther.* 2005, **16**: 1212-1218.

30. Okada T, Nonaka-Sarukawa M, Uchibori R, Kinoshita K, Hayashita-Kinoh H, Nitahara-Kasahara Y, Takeda S, and Ozawa K: *Scalable purification of adeno-associated virus serotype 1 (AAV1) and AAV8 vectors, using dual ion-exchange adsorptive membranes.* *Hum Gene Ther.* 2009, **20**: 1013-1021.

31. Hayashita-Kinoh H, Yugeta N, Okada H, Nitahara-Kasahara Y, Chiyo T, Okada T, and Takeda S: *Intra-amniotic rAAV-mediated microdystrophin gene transfer improves canine X-linked muscular dystrophy and may induce immune tolerance.* *Mol Ther.* 2015, **23**: 627-637.

32. Kobayashi M, Nakamura A, Hasegawa D, Fujita M, Orima H, and Takeda S: *Evaluation of dystrophic dog pathology by fat-suppressed T2-weighted imaging.* *Muscle Nerve.* 2009, **40**: 815-826.

33. Kuraoka M, Nitahara-Kasahara Y, Tachimori H, Kato N, Shibasaki H, Shin A, Aoki Y, Kimura E, and Takeda S: *Accelerometric outcomes of motor function related to clinical evaluations and muscle involvement in dystrophic dogs.* *PLoS One.* 2018, **13**: e0208415.

34. Choi J, Costa ML, Mermelstein CS, Chagas C, Holtzer S, and Holtzer H: *MyoD converts primary dermal fibroblasts, chondroblasts, smooth muscle, and retinal pigmented epithelial cells into striated mononucleated myoblasts and multinucleated myotubes.* *Proc Natl Acad Sci U S A.* 1990, **87**: 7988-7992.

35. Balana B, Nicoletti C, Zahanich I, Graf EM, Christ T, Boxberger S, and Ravens U: *5-Azacytidine induces changes in electrophysiological properties of human mesenchymal stem cells.* *Cell Res.* 2006, **16**: 949-960.

36. Sasse S, Skorska A, Lux CA, Steinhoff G, David R, and Gaebel R: *Angiogenic Potential of Bone Marrow Derived CD133(+) and CD271(+) Intramyocardial Stem Cell Trans-Plantation Post MI.* *Cells.* 2019, **9**.

37. Luo Q, Zhang B, Kuang D, and Song G: *Role of Stromal-Derived Factor-1 in Mesenchymal Stem Cell Paracrine-Mediated Tissue Repair.* *Curr Stem Cell Res Ther.* 2016, **11**: 585-592.

38. Liu H, Liu S, Li Y, Wang X, Xue W, Ge G, and Luo X: *The role of SDF-1-CXCR4/CXCR7 axis in the therapeutic effects of hypoxia-preconditioned mesenchymal stem cells for renal ischemia/reperfusion injury.* *PLoS One.* 2012, **7**: e34608.

39. Hunger C, Odemis V, and Engele J: *Expression and function of the SDF-1 chemokine receptors CXCR4 and CXCR7 during mouse limb muscle development and regeneration.* *Exp Cell Res.* 2012, **318**: 2178-2190.
Supplementary Information

Additional file 1. In vivo bioluminescence imaging for the detection of injected MSCs

Additional file 2. Enhanced engraftment of IL-10-MSCs

Additional file 3. MSC survival in skeletal muscle tissue

Additional file 4. IL-10 expression in IL-10-MSC-treated muscle tissue

Additional file 5. Characterization of gene-transduced MSCs

Additional file 6. Serum chemistry data from the hDPSC-treated CXMD_{J} model

Additional file 7. Reverse transcription PCR for evaluating human specific dystrophin expression

Additional file 8. Estimated isometric tetanic force in hDPSC-treated CXMD_{J}

Additional file 9. 15-meter running speed of hDPSC-treated CXMD_{J}

Supplemental Table 1. Running speed (15-m) of dogs aged 12 to 44 months

Table

Table 1. Summary of transplantation experiments
| Dog ID   | Sex | Age\(^a\) | BW\(^b\) | Cell                        | Cell numbers | Interval | Injection numbers | Route |
|----------|-----|-----------|---------|-----------------------------|--------------|----------|-------------------|-------|
| 4502MN   | M   | 51        | 11.3    | IL-10-CD271\(^+\)MSCs, MyoD-CD271\(^+\)MSCs | \(2.5 \times 10^7\) cells | -        | 1                 | i.m.\(^c\) |
| 5601MN   | M   | 40        | 11.2    | IL-10-CD271\(^+\)MSCs, MyoD-CD271\(^+\)MSCs | \(4.0 \times 10^6 - 10.0 \times 10^6\) cells | -        | 2                 | i.m.\(^c\) |
| 14103MN  | M   | 3         | 5.0     | -                           | -            | -        | -                 | -     |
| 14102MA  | M   | 3         | 3.3     | -                           | -            | -        | -                 | -     |
| 14105MA  | M   | 3         | 3.4     | hDPSCs                      | \(4.0 \times 10^6\) cells/kg | 2 weeks   | 9                 | i.v.\(^d\) |
| 14108MA  | M   | 3         | 3.5     | IL-10-hDPSCs                | \(4.0 \times 10^6\) cells/kg | 2 weeks   | 9                 | i.v.\(^d\) |

M, male; \(^a\)Age at injection (months); \(^b\)BW, body weight at first injection (kg); \(^c\)i.m, intramuscular injection; \(^d\)i.v., intravenous injection